Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Blood (2024) 144 (Supplement 1): 4.

https://doi.org/10.1182/blood-2024-208913

Published: 2024

Journal Articles

EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

Siena Nason, Ziqi Yang, Guido Ghilardi, Luca Paruzzo, Alberto Carturan, Eugenio Fardella, Puneeth Guruprasad, Anushka Anant Padmanabhan, Tatiana Blanchard, Gerald Linette, Beatriz M. Carreno, Sandra Susanibar-Adaniya, Alfred L. Garfall, Marco Ruella, Patrizia Porazzi

Blood (2024) 144 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2024-206011

Published: 2024

Journal Articles

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Blood (2024) 144 (Supplement 1): 7221.

https://doi.org/10.1182/blood-2024-201063

Published: 2024

Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Blood (2024) 144 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2024-206608

Published: 2024

Journal Articles

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Alberto Carturan, Mathew G. Angelos, Raymone Pajarillo, Jesse Rodriguez, Jaryse Harris, Yunlin Zhang, Ekta Singh, Andrew Lee, Ositadimma Ugwuanyi, Ruchi P. Patel, Puneeth Guruprasad, Jean Lemoine, Jong Hyun Cho, Patrizia Porazzi, Stephen J. Schuster, Marco Ruella

Blood (2024) 144 (Supplement 1): 504.

https://doi.org/10.1182/blood-2024-206061

Published: 2024

Journal Articles

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

Patrizia Porazzi, Yusuke Isshiki, Guido Ghilardi, Siena Nason, Ziqi Yang, Alberto Carturan, Linhui Chen, Yunlin Zhang, Ruchi P. Patel, Puneeth Guruprasad, Ositadimma Ugwuanyi, Ivan J Cohen, Stephen J Schuster, Ari M Melnick, Wendy BÃ©guelin, Marco Ruella

Blood (2023) 142 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2023-182440

Published: 2023

Journal Articles

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Yusuke Isshiki, Patrizia Porazzi, Xi Chen, Matthew Teater, Ioannis Karagiannidis, Henna S. Nam, Ari M Melnick, Marco Ruella, Wendy BÃ©guelin

Blood (2023) 142 (Supplement 1): 432.

https://doi.org/10.1182/blood-2023-190610

Published: 2023

Journal Articles

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

Blood (2023) 142 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2023-182234

Published: 2023

Journal Articles

Senza5 TM CART5 : An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity

Adam E. Snook, Ruchi P. Patel, Guido Ghilardi, Aditya Nimmagadda, Steven Yang, Dean Qian, Patrizia Porazzi, Rosemary Mazanet, Stephen J Schuster, Stefan K. Barta, Trang Vu, Marco Ruella, Nicholas A. Siciliano

Blood (2023) 142 (Supplement 1): 3462.

https://doi.org/10.1182/blood-2023-190386

Published: 2023

Journal Articles

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Ruchi P. Patel, Guido Ghilardi, Yunlin Zhang, Puneeth Guruprasad, Mathew G. Angelos, Raymone Pajarillo, Khatuna Gabunia, Chong Xu, Tatiana Blanchard, John Scholler, Patrizia Porazzi, Gerald Linette, Beatriz M. Carreno, Marco Ruella

Blood (2023) 142 (Supplement 1): 102.

https://doi.org/10.1182/blood-2023-186611

Published: 2023

Journal Articles

Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer

Blood (2023) 142 (Supplement 1): 768.

https://doi.org/10.1182/blood-2023-189633

Published: 2023

Journal Articles

Precision Targeting of the Malignant Clone in Diffuse Large B Cell Lymphoma Using Chimeric Antigen Receptor T Cells Against the Clonotypic IGHV4-34 B Cell Receptor

Ivan J Cohen, Audrey C Bochi-Layec, Ki Hyun Kim, Scott Jenks, Ositadimma Ugwuanyi, Guido Ghilardi, Giulia Gabrielli, Jaryse Harris, Li-Ping Wang, Yunlin Zhang, Raymone Pajarillo, Elisavet Vlachonikola, Patrizia Porazzi, Ignacio Sanz, Paolo Ghia, Kostas Stamatopoulos, Stephen J Schuster, Marco Ruella

Blood (2023) 142 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2023-187618

Published: 2023

Journal Articles

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 2096.

https://doi.org/10.1182/blood-2023-189369

Published: 2023

Journal Articles

Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Blood (2022) 140 (Supplement 1): 7371–7373.

https://doi.org/10.1182/blood-2022-167601

Published: 2022

Journal Articles

Clinical Development of Senza5 TM CART5: a Novel Dual Population CD5 CRISPR-Cas9 Knocked out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell Lymphomas

Ruchi P. Patel, Guido Ghilardi, Patrizia Porazzi, Steven Yang, Dean Qian, Raymone Pajarillo, Michael Wang, Yunlin Zhang, Stephen J. Schuster, Stefan K. Barta, Aditya Nimmagadda, Adam Snook, Nicholas A. Siciliano, Marco Ruella

Blood (2022) 140 (Supplement 1): 1604–1605.

https://doi.org/10.1182/blood-2022-166605

Published: 2022

Journal Articles

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

Marco De Dominici, Patrizia Porazzi, Youcai Xiao, Allen Chao, Hsin-Yao Tang, Gaurav Kumar, Paolo Fortina, Orietta Spinelli, Alessandro Rambaldi, Luke F. Peterson, Svetlana Petruk, Camilla Barletta, Alexander Mazo, Gino Cingolani, Joseph M. Salvino, Bruno Calabretta

Blood (2020) 135 (18): 1560–1573.

https://doi.org/10.1182/blood.2019003604

Published: 2020

Includes: Supplemental data

Journal Articles

Targeting CDK6 and BCL2 Exploits the “MYB Addiction” of Ph+ Acute Lymphoblastic Leukemia

Marco De Dominici, MS, Angela Rachele Soliera, PhD, Patrizia Porazzi, PhD, Samanta A. Mariani, PhD, Sankar Addya, PhD, Luke F. Peterson, PhD, Orietta Spinelli, PhD, Alessandro Rambaldi, MD Prof, Giovanni Martinelli, MD, Ilaria Iacobucci, PhD, Anna Ferrari, PhD, Bruno Calabretta, MD PhD

Blood (2017) 130 (Supplement 1): 2490.

https://doi.org/10.1182/blood.V130.Suppl_1.2490.2490

Published: 2017

Journal Articles

Zebrafish Ortholog of Human DOT1L Regulates Primitive and Transient Definitive Hematopoiesis and Controls hoxa9 and meis1 Expression

Giulia Morello, BSc, Patrizia Porazzi, PhD, Enrico Moro, PhD, Francesco Argenton, PhD, Giuseppe Basso, MD, Carolyn A. Felix, MD, Giuseppe Germano, PhD

Blood (2012) 120 (21): 849.

https://doi.org/10.1182/blood.V120.21.849.849

Published: 2012

NARROW

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

Senza5 TM CART5 : An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer

Precision Targeting of the Malignant Clone in Diffuse Large B Cell Lymphoma Using Chimeric Antigen Receptor T Cells Against the Clonotypic IGHV4-34 B Cell Receptor

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Clinical Development of Senza5 TM CART5: a Novel Dual Population CD5 CRISPR-Cas9 Knocked out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell Lymphomas

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

Targeting CDK6 and BCL2 Exploits the “MYB Addiction” of Ph+ Acute Lymphoblastic Leukemia

Zebrafish Ortholog of Human DOT1L Regulates Primitive and Transient Definitive Hematopoiesis and Controls hoxa9 and meis1 Expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only